MORGAN STANLEY PLC/CALL/EDWARDS LIFESCIENCES/130/0.1/21.03.25 | Real-time Bid/Ask 04:25:20 13/06/2024 pm IST | ||
| 0.197 EUR / 0.23 EUR | -3.17% |
|
| Current month | +32.34% | ||
| 1 month | +79.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 12/24/12 | 0.221 | +8.87% |
| 11/24/11 | 0.203 | +15.34% |
| 10/24/10 | 0.176 | -6.88% |
| 07/24/07 | 0.189 | +2.72% |
| 06/24/06 | 0.184 | +0.55% |
Delayed Quote Börse Stuttgart
Last update June 12, 2024 at 10:15 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | Morgan Stanley |
| WKN | MB8GSH |
| ISIN | DE000MB8GSH9 |
| Date issued | 07/07/2023 |
| Strike | 130 $ |
| Maturity | 21/03/2025 (282 Days) |
| Parity | 10 : 1 |
| Emission price | 0.44 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.53 € |
|---|---|
| Lowest since issue | 0.1 € |
| Spread | 0.032 € |
| Spread % | 13.91% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
87.77
USD
Average target price
96.31
USD
Spread / Average Target
+9.73%
- Stock Market
- Warrants
- Warrant
